Atopic Dermatitis-US Drug Forecast and Market Analysis to 2024 is a new market research publication announced by Reportstack. Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
By the mid-to-late term of this report 2014 to 2024 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the adult moderate and severe treatment landscape and to slowly enter the market for younger patients with milder forms of the disease.
Complete report available @ Atopic Dermatitis-US Drug Forecast and Market Analysis to 2024
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US.
The US dominates the global atopic dermatitis market by value and volume, with an estimated market size of $2.1 billion and a diagnosed prevalent population of 5.8 million in 2014, of which 3.7 million patients were drug-treated.
With guidelines recommending topical corticosteroids for the majority of patients and moisturizers or emollients at first line of therapy, these drug classes contributed 66.64% to the 2014 sales value. However, these classes represent the crowded, saturated, generic portion of the US atopic dermatitis market, with little room for innovative products.
Scope
- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product Atopic Dermatitiscription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Atopic Dermatitis market.
- Detailed information on the key drugs in the US including product Atopic Dermatitiscription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Atopic Dermatitis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in US.
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in US.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
No comments:
Post a Comment